daunorubicin has been researched along with dexrazoxane in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Austin, CA; Bavlovič Piskáčková, H; Jirkovská, A; Jirkovský, E; Karabanovich, G; Korábečný, J; Kubeš, J; Kučera, T; Melnikova, I; Nováková, L; Roh, J; Šimůnek, T; Skalická, V; Škoda, J; Štěrba, M | 1 |
| Haskova, P; Jansova, H; Machacek, M; Mackova, E; Simunek, T; Sterba, M; Tichotova, L; Vavrova, A | 1 |
| Adamcová, M; Chládek, J; Geršl, V; Hroch, M; Jansová, H; Jirkovská-Vávrová, A; Jirkovský, E; Lenčová-Popelová, O; Mazurová, Y; Pokorná, Z; Šimůnek, T; Štěrba, M; Vostatková-Tichotová, L | 1 |
| Bures, J; Jansova, H; Jirkovska, A; Karabanovich, G; Kovarikova, P; Roh, J; Sestak, V; Simunek, T; Sterba, M | 1 |
| Caballero Romero, Á; Cabeza Barrera, J; Delgado Ureña, MT; Librada Porriño-Bustamante, M; Megías Fernández, MT; Salmerón García, A | 1 |
2 review(s) available for daunorubicin and dexrazoxane
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Extravasation accidents with liposomal/liposomal pegylated anthracyclines treated with dexrazoxane: an overview and outcomes.
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Daunorubicin; Dexrazoxane; Doxorubicin; Extravasation of Diagnostic and Therapeutic Materials; Humans; Liposomes; Polyethylene Glycols | 2018 |
6 other study(ies) available for daunorubicin and dexrazoxane
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase IIβ Interactions.
Topics: Animals; Animals, Newborn; Cardiotonic Agents; Cardiotoxicity; Cell Line, Tumor; Cell Proliferation; Daunorubicin; Diketopiperazines; DNA Topoisomerases, Type II; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Myocytes, Cardiac; Piperazines; Protein Binding; Rats, Wistar; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2021 |
Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells.
Topics: Animals; Animals, Newborn; Anthracyclines; Biocatalysis; Caspases; Cell Cycle; Cell Proliferation; Cell Survival; Cells, Cultured; Daunorubicin; Dexrazoxane; DNA Topoisomerases, Type II; Doxorubicin; Drug Interactions; Flow Cytometry; Glutathione; Glutathione Disulfide; HL-60 Cells; Humans; Myocytes, Cardiac; Piperazines; Rats; Rats, Wistar; Thiobarbiturates; Topoisomerase II Inhibitors | 2013 |
Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane.
Topics: Animals; Antibiotics, Antineoplastic; Cardiotonic Agents; Cardiotoxicity; Daunorubicin; Dexrazoxane; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Administration Schedule; Infusions, Intravenous; Male; Myocardium; Myocytes, Cardiac; Nitrates; Rabbits; Sodium Nitrite | 2016 |
Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite.
Topics: Animals; Animals, Newborn; Anthracyclines; Cardiotonic Agents; Cardiotoxicity; Cell Proliferation; Cells, Cultured; Daunorubicin; Dexrazoxane; Diketopiperazines; DNA Topoisomerases, Type II; Iron; Iron Chelating Agents; Myocytes, Cardiac; Rats; Rats, Wistar; Structure-Activity Relationship | 2017 |